Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19
Mohamed Elmenshawy, Sara Samir; Ahmed Abdelsalam, Mohamed Farouk; El Nagdy, Tarek Refaat; Salam Elgohary, Mohamed Abdel; El-kholy, Amal; Sabri, Nagwa;
Abstract
Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19. Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period. Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia. Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir. Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease. Trial registration number:NCT04973462.
Other data
| Title | Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19 | Authors | Mohamed Elmenshawy, Sara Samir; Ahmed Abdelsalam, Mohamed Farouk; El Nagdy, Tarek Refaat; Salam Elgohary, Mohamed Abdel; El-kholy, Amal; Sabri, Nagwa | Keywords | Coronavirus disease 2019 | COVID-19 | CT-scan | dyspnea | fever | oseltamivir | PCR | pneumonia | SARS-CoV-2 | triazavirin | Issue Date | 1-Jan-2024 | Journal | Future Science Oa | ISSN | 2056-5623 | DOI | 10.1080/20565623.2024.2418798 | PubMed ID | 39539144 | Scopus ID | 2-s2.0-85209947365 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.